ObsEva initiates Phase 1 clinical program of OBE022 for the treatment of preterm labor
28 July 2016 | By ObsEva
ObsEva initiates Phase 1 clinical program of OBE022, a first-in-class orally active Prostaglandin F2alpha antagonist, for the treatment of preterm labor...